Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations

被引:11
|
作者
van Dijk, Sabine J. [1 ]
Boontje, Nicky M. [1 ]
Heymans, Martijn W. [2 ]
ten Cate, Folkert J. [3 ]
Michels, Michelle [3 ]
dos Remedios, Cris [4 ]
Dooijes, Dennis [5 ]
van Slegtenhorst, Marjon A. [6 ]
van der Velden, Jolanda [1 ,7 ]
Stienen, Ger J. M. [1 ,8 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Physiol Lab, Inst Cardiovasc Res, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, NL-1081 BT Amsterdam, Netherlands
[3] Erasmus MC, Ctr Thorax, Rotterdam, Netherlands
[4] Univ Sydney, Muscle Res Unit, Inst Biomed Res, Sydney, NSW 2006, Australia
[5] Med Ctr Utrecht, Utrecht, Netherlands
[6] Erasmus MC, Rotterdam, Netherlands
[7] ICIN Netherlands Heart Inst, Utrecht, Netherlands
[8] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands
来源
关键词
Cardiac muscle; Cross-bridge; Muscle contraction; MyBP-C mutation; BINDING-PROTEIN-C; KINASE-A PHOSPHORYLATION; HEART-FAILURE; TROPONIN-I; STRETCH ACTIVATION; F-ACTIN; MYOSIN; MUSCLE; ABLATION; GENE;
D O I
10.1007/s00424-013-1391-0
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Mutations in the MYBPC3 gene, encoding cardiac myosin binding protein C (cMyBP-C) are frequent causes of hypertrophic cardiomyopathy (HCM). Previously, we have presented evidence for reduced cMyBP-C expression (haploinsufficiency), in patients with a truncation mutation in MYBPC3. In mice, lacking cMyBP-C cross-bridge kinetics was accelerated. In this study, we investigated whether cross-bridge kinetics was altered in myectomy samples from HCM patients harboring heterozygous MYBPC3 mutations (MYBPC3(mut)). Isometric force and the rate of force redevelopment (k (tr)) at different activating Ca2+ concentrations were measured in mechanically isolated Triton-permeabilized cardiomyocytes from MYBPC3(mut) (n = 18) and donor (n = 7) tissue. Furthermore, the stretch activation response of cardiomyocytes was measured in tissue from eight MYBPC3(mut) patients and five donors to assess the rate of initial force relaxation (k (1)) and the rate and magnitude of the transient increase in force (k (2) and P (3), respectively) after a rapid stretch. Maximal force development of the cardiomyocytes was reduced in MYBPC3(mut) (24.5 +/- 2.3 kN/m(2)) compared to donor (34.9 +/- 1.6 kN/m(2)). The rates of force redevelopment in MYBPC3(mut) and donor over a range of Ca2+ concentrations were similar (k (tr) at maximal activation: 0.63 +/- 0.03 and 0.75 +/- 0.09 s(-1), respectively). Moreover, the stretch activation parameters did not differ significantly between MYBPC3(mut) and donor (k (1): 8.5 +/- 0.5 and 8.8 +/- 0.4 s(-1); k (2): 0.77 +/- 0.06 and 0.74 +/- 0.09 s(-1); P (3): 0.08 +/- 0.01 and 0.09 +/- 0.01, respectively). Incubation with protein kinase A accelerated k (1) in MYBPC3(mut) and donor to a similar extent. Our experiments indicate that, at the cMyBP-C expression levels in this patient group (63 +/- 6 % relative to donors), cross-bridge kinetics are preserved and that the depressed maximal force development is not explained by perturbation of cross-bridge kinetics.
引用
下载
收藏
页码:1619 / 1633
页数:15
相关论文
共 50 条
  • [31] Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy
    Lin, Jia
    Zheng, Dong-Dong
    Tao, Qin
    Yang, Jun-Hua
    Jiang, Wen-Ping
    Yang, Xiang-Jun
    Song, Jian-Ping
    Jiang, Ting-Bo
    Li, Xun
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 (10) : 518 - 522
  • [32] Sensitivity and Specificity of Denaturing HPLC to Detect MYBPC3 Gene Mutations in Hypertrophic Cardiomyopathy
    Bahrudin, Udin
    Mizuta, Einosuke
    Ariani, Mahayu Dewi
    Nindita, Yora
    Hisatome, Ichiro
    YONAGO ACTA MEDICA, 2009, 52 (04) : 121 - 125
  • [33] Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
    Carballo, S
    Blair, E
    Watkins, H
    CIRCULATION, 2005, 112 (17) : U471 - U471
  • [34] Integrated analysis of transcriptional regulation in hypertrophic cardiomyopathy cased by truncating MYBPC3 mutations
    Pei, J.
    Schuldt, M.
    Nagyova, E.
    Gu, Z.
    Bouhaddani, S. E.
    Calis, J.
    Dorsch, L. M.
    van den Dungen, N. A. M.
    Lansu, N.
    Boukens, B. J.
    Efimov, I. R.
    Michels, M.
    Verhaar, M. C.
    de Weger, R.
    Vink, A.
    Uh, H. W.
    Cheng, C.
    Kuster, D. W.
    Mokry, M.
    van der Velden, J.
    Asselbergs, F. W.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 747 - 747
  • [35] MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy
    Wang, P
    Zou, YB
    Fu, CY
    Zhou, XL
    Hui, RT
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (02) : 796 - 799
  • [36] Depressed Contractility at Low-Load Spontaneous Oscillatory Contractions in Human Hypertrophic Cardiomyopathy with MYBPC3 Mutations
    Li, Amy
    Bos, J. Martijn
    Ackerman, Michael J.
    Braet, Filip
    Kekic, Murat
    Ishiwata, Shin'ichi
    dos Remedios, Cristobal G.
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 347A - 348A
  • [37] A low prevalence of MYH7/MYBPC3 mutations among Familial Hypertrophic Cardiomyopathy patients in India
    Bashyam, Murali D.
    Purushotham, Guroji
    Chaudhary, Ajay K.
    Rao, Katika Madhumohan
    Acharya, Vishal
    Mohammad, Tabrez A.
    Nagarajaram, Hampapathalu A.
    Hariram, Vuppaladadhiam
    Narasimhan, Calambur
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2012, 360 (1-2) : 373 - 382
  • [38] A low prevalence of MYH7/MYBPC3 mutations among Familial Hypertrophic Cardiomyopathy patients in India
    Murali D. Bashyam
    Guroji Purushotham
    Ajay K. Chaudhary
    Katika Madhumohan Rao
    Vishal Acharya
    Tabrez A. Mohammad
    Hampapathalu A. Nagarajaram
    Vuppaladadhiam Hariram
    Calambur Narasimhan
    Molecular and Cellular Biochemistry, 2012, 360 : 373 - 382
  • [39] Clinical presentation and outcomes in paediatric-onset hypertrophic cardiomyopathy associated with MYBPC3 mutations
    Field, E.
    Norrish, G.
    Jager, J.
    Fell, H.
    Lord, E.
    Walsh, H.
    Cervi, E.
    Kaski, J. P.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1322 - 1322
  • [40] Novel pathogenic variant of MYBPC3 responsible for hypertrophic cardiomyopathy
    Yang, Xiaofei
    Li, Zhenghao
    Wang, Qingfa
    Zhang, Yongfa
    Zhao, Cuifen
    CARDIOLOGY IN THE YOUNG, 2022, 32 (04) : 539 - 544